EUVIMEDOpdag EUVIMED
Multizentrische StudieOpen access · CC BY 4.0

One‐Year Effectiveness of Upadacitinib in Perianal Crohn's Disease: A Real‐World GETAID Study

Nicolas Richard iD, Philippe Seksik, Romain Altwegg, Maria Nachury, David Laharie iD, Stéphane Nancey, Benoît Coffin, Anne-Laure Pelletier iD, Mathieu Uzzan iD, Aurélien Amiot iD, Morgane Amil, Lucine Vuitton and 2 more

Alimentary Pharmacology & Therapeutics · 2026-07 · 64 (2) · 235-242

DOI: 10.1111/apt.70682 ↗

At a glance

Multizentrische Studie in Alimentary Pharmacology & Therapeutics, published online on 2026-04-27. Written by Nicolas Richard and 13 co-authors. Institution: Department of Gastroenterology, University Rouen Normandie, INSERM, ADEN UMR1073, "Nutrition, Inflammation and Microbiota-Gut-Brain Axis", CHU Rouen,…. Major MEDLINE topics: Crohn Disease, Heterocyclic Compounds, 3-Ring. Cited 10 times so far (Crossref); 23 references. The full text is freely available (open access, CC BY 4.0).

AbstractSubjectsBibliografiske oplysningerCiteRelated studies

Abstract (original language)

Introduction

Upadacitinib (UPA) is effective for treating luminal Crohn's disease (CD), but data on perianal CD (pCD) remain limited.

Methods

All consecutive patients with active pCD (primary and/or secondary lesions) treated with UPA across 13 French centres between September 2022 and August 2025 were included in a retrospective cohort study. Clinical remission was defined as absence of fistula drainage (spontaneous or on gentle pressure) and healing of anal ulcerations without initiation of new therapy. Clinical response was defined as ≥ 50% improvement in fistulas and/or ulcerations based on physician assessment. Clinical outcomes were analysed using non‐responder imputation, and magnetic resonance imaging (MRI) outcomes as observed.

Results

Among the 59 patients included, 43 (73%) had fistulizing pCD and 16 (27%) isolated anal ulcerations. All patients were previously exposed to at least one biologic and 79% of those with fistulizing pCD underwent prior perianal surgery. In patients with fistulizing pCD, clinical remission was achieved in 11/43 (26%) and 11/43 (26%) patients at 6 and 12 months, respectively, clinical response in 21/43 (49%) and 13/43 (30%) patients. At 12 months, MRI response was documented in 9/13 (69%) and MRI remission in 1/13 (8%) patients with fistulizing pCD. Among patients with fistulizing pCD, no factors predicted clinical remission. Among patients with isolated anal ulcerations, complete healing occurred in 5/16 (31%) at 3 months, 4/16 (25%) at 6 months and 4/16 (25%) at 12 months.

Conclusion

In this real‐world cohort of refractory pCD, UPA achieved clinical remission in one‐quarter of patients at 1 year.

Subjects

MeSH terms (MEDLINE)

Crohn DiseaseHeterocyclic Compounds, 3-RingHumansMaleRetrospective StudiesFemaleAdultTreatment OutcomeFranceMagnetic Resonance ImagingMiddle AgedRemission InductionRectal Fistula

Author keywords

Crohn's diseasefistulizing perianal Crohn's diseaseupadacitinib

Substances

upadacitinibHeterocyclic Compounds, 3-Ring

Authors and institutions

  • Department of Gastroenterology, University Rouen Normandie, INSERM, ADEN UMR1073, "Nutrition, Inflammation and Microbiota-Gut-Brain Axis", CHU Rouen, Rouen, France.
  • Department of Gastroenterology, CRSA, Sorbonne Université, INSERM UMRS-938, Gut, Liver & Microbiome Research (GLIMMER) FHU, APHP, Saint-Antoine Hospital, Paris, France.
  • Department of Gastroenterology, CHU of Montpellier, Montpellier, France.
  • University of Lille, INSERM, Lille University Hospital, U1286 - INFINITE - Institute for Translational Research in Inflammation, Lille, France.
  • Department of Gastroenterology, CHU de Bordeaux, Haut-Lévêque Hospital, University of Bordeaux, Bordeaux, France.
  • Department of Gastroenterology, Lyon-Sud Hospital, CHU of Lyon, Lyon, France.

ORCID profiles: Nicolas Richard, David Laharie, Anne-Laure Pelletier, Mathieu Uzzan, Aurélien Amiot

Cite

APA

Richard, N., Seksik, P., Altwegg, R., Nachury, M., Laharie, D., Nancey, S., Coffin, B., Pelletier, A. L., Uzzan, M., Amiot, A., Amil, M., Vuitton, L., Fumery, M., & Bozon, A. (2026). One‐Year Effectiveness of Upadacitinib in Perianal Crohn's Disease: A Real‐World GETAID Study. Alimentary Pharmacology & Therapeutics, 64(2), 235-242. https://doi.org/10.1111/apt.70682

Vancouver

Richard N, Seksik P, Altwegg R, Nachury M, Laharie D, Nancey S, et al. One‐Year Effectiveness of Upadacitinib in Perianal Crohn's Disease: A Real‐World GETAID Study. Alimentary Pharmacology & Therapeutics. 2026;64(2):235-242. doi:10.1111/apt.70682

BibTeX
@article{Richard2026,
  author = {Richard, Nicolas and Seksik, Philippe and Altwegg, Romain and Nachury, Maria and Laharie, David and Nancey, Stéphane and Coffin, Benoît and Pelletier, Anne-Laure and Uzzan, Mathieu and Amiot, Aurélien and Amil, Morgane and Vuitton, Lucine and Fumery, Mathurin and Bozon, Anne},
  title = {One‐Year Effectiveness of Upadacitinib in Perianal Crohn's Disease: A Real‐World GETAID Study},
  journal = {Alimentary Pharmacology & Therapeutics},
  year = {2026},
  volume = {64},
  number = {2},
  pages = {235--242},
  doi = {10.1111/apt.70682}
}
Start for free →